MedTrace Logo

A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome

NCT00578825 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 340

Last updated 2013-08-22

No results posted yet for this study

Summary

The study aims to examine whether the combination of Lopinavir/Ritonavir plus Ribavirin for treatment of severe acute respiratory syndrome (SARS) is superior to placebo.

Conditions

  • Severe Acute Respiratory Syndrome

Interventions

DRUG

Lopinavir / Ritonavir plus Ribavirin

Sponsors & Collaborators

  • Hospital Authority, Hong Kong

    lead OTHER_GOV

Principal Investigators

  • Wai Cho Yu, Dr · Department of Medicine & Geriatrics, Princess Margaret Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00578825 on ClinicalTrials.gov